Alexander DeLuca, M.D.
Addiction, Pain, & Public Health website

[Home] [Library]  [Slides]  [Search]  [Medline]  [Links]
 
[Statements of Purpose, Ownership, Sponsorship. Privacy,  Email Confidentiality, and Advertising Policies]

 
Cannabinoids In Medicine: A Review Of Their Therapeutic Potential
[HTML Abstract and References and Link to Full Text PDF]
 

 
Mohamed Ben Amar; Journal of Ethnopharmacology, 102(1-2), 1-25; 2006-04-21. Posted: 2006-06-14
[Identifier: http://www.doctordeluca.com/Library/WOD/WPS3-MedMj/CannabinoidsMedMetaAnalysis06.htm]

Related resources:  Drug War Academic Literature and Official Reports archives 
 
See also:
Pot Smoking Not Linked to Lung Cancer - Salynn Boyles; WebMD; 2006-05-23
 
Nonacute (Residual) Neuropsychological Effects of Cannabis Use - Gonzalez et al.; J.Clin.Pharm.; 2002
 
Marijuana Smoking and Head and Neck Cancer - Hashibe, et al.; J. Clinical Pharmacology; 2002
 
WAR ON PAIN SUFFERERS #3 - Medical Marijuana, 2000-2006
 
War on Doctors and Pain Crisis Weekly - RSS feed:   HTML view:
Harm Reduction for Alcohol and Drug Use Disorders Weekly - RSS feed:   HTML view:
 

[Full Text of this Article in Adobe PDF format]

Abstract

In order to assess the current knowledge on the therapeutic potential of cannabinoids, a meta-analysis was performed through Medline and PubMed up to July 1, 2005. The key words used were cannabis, marijuana, marihuana, hashish, hashich, haschich, cannabinoids, tetrahydrocannabinol, THC, dronabinol, nabilone, levonantradol, randomised, randomized, double-blind, simple blind, placebo-controlled, and human. The research also included the reports and reviews published in English, French and Spanish. For the final selection, only properly controlled clinical trials were retained, thus open-label studies were excluded.

Seventy-two controlled studies evaluating the therapeutic effects of cannabinoids were identified. For each clinical trial, the country where the project was held, the number of patients assessed, the type of study and comparisons done, the products and the dosages used, their efficacy and their adverse effects are described. Cannabinoids present an interesting therapeutic potential as antiemetics, appetite stimulants in debilitating diseases (cancer and AIDS), analgesics, and in the treatment of multiple sclerosis, spinal cord injuries, Tourette's syndrome, epilepsy and glaucoma.

References

Abrams et al., 2003 D.I. Abrams, J.F. Hilton, R.J. Leiser, S.B. Shade, T.A. Elbeik, F.T. Aweeka, N.L. Benowitz, B.M. Bredt, B. Korel, J.A. Aberg, S.G. Deeks, T.F. Mitchell, K. Mulligan, P. Baccheti, J.M. McCune and M. Schambelan, Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial, Annals of Internal Medicine 139 (2003), pp. 258–266. Abstract-MEDLINE

Ahmedzai et al., 1983 S. Ahmedzai, D.L. Carlyle, I.T. Calder and F. Foran, Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy, British Journal of Cancer 48 (1983), pp. 657–663. Abstract-MEDLINE | Abstract-EMBASE

Arnold, 2005 J.C. Arnold, The role of endocannabinoid transmission in cocaine addiction, Pharmacology, Biochemistry and Behavior 81 (2005), pp. 396–406. SummaryPlus | Full Text + Links | PDF (180 K)

Arseneault et al., 2002 L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi and T.E. Mofitt, Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study, British Medical Journal 325 (2002), pp. 1212–1213. Abstract-MEDLINE | Abstract-EMBASE | Abstract-Elsevier BIOBASE | Full Text via CrossRef

Ashton, 2001 C.H. Ashton, Pharmacology and effects of cannabis: a brief review, British Journal of Psychiatry 178 (2001), pp. 101–106. Abstract-MEDLINE | Abstract-EMBASE | Abstract-Elsevier BIOBASE | Full Text via CrossRef

Bagshaw and Hagen, 2002 S.M. Bagshaw and N.A. Hagen, Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature, Journal of Palliative Care 18 (2002), pp. 111–122. Abstract-MEDLINE

Baker et al., 2003 D. Baker, G. Pryce, G. Giovannoni and A.J. Thompson, The therapeutic potential of cannabis, Lancet Neurology 2 (2003), pp. 291–298. SummaryPlus | Full Text + Links | PDF (572 K)

Beal et al., 1995 J.E. Beal, R. Olson, L. Laubenstein, J.O. Morales, P. Bellman, B. Yangco, L. Lefkowitz, T.F. Plasse and K.V. Shepard, Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS, Journal of Pain and Symptom Management 10 (1995), pp. 89–97. Abstract | PDF (564 K)

Beard et al., 2003 S. Beard, A. Hunn and J. Wight, Treatments for spasticity and pain in multiple sclerosis: a systematic review, Health Technology Assessment 7 (2003), pp. 1–111.

Beaulieu and Ware, 2004 P. Beaulieu and M. Ware, La recherche médicale sur le cannabis dans le traitement de la douleur au Canada: passé, présent et futur?. In: M. Ben Amar, Editor, Cannabis, Drogues, Santé et Société, Montreal (2004), pp. 99–123www.drogues-sante-societe.org.

Ben Amar, 2004 M. Ben Amar, Pharmacologie du cannabis et synthèse des analyses des principaux comités d’experts. In: M. Ben Amar, Editor, Cannabis, Drogues, Santé et Société, Montreal (2004), pp. 9–60www.drogues-sante-societe.org.

Ben Amar and Léonard, 2002 M. Ben Amar and L. Léonard, Chapter 16: Cannabis. In: L. Léonard and M. Ben Amar, Editors, Les Psychotropes: Pharmacologie et Toxicomanie, Les Presses de l’Université de Montréal, Montreal (2002), pp. 571–627.

Berman et al., 2004 J.S. Berman, C. Symonds and R. Birch, Efficacy of two cannabis based medicinal extracts for relief on central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial, Pain 112 (2004), pp. 299–306. SummaryPlus | Full Text + Links | PDF (170 K)

Bifulco and Di Marzo, 2002 M. Bifulco and V. Di Marzo, Targeting the endocannabinoid system in cancer therapy: a call for further research, Nature Medicine 8 (2002), pp. 547–550. Abstract-EMBASE | Abstract-Elsevier BIOBASE | Abstract-MEDLINE | Full Text via CrossRef

Blake et al., 2005 Blake, D.R., Robson, P., Ho, M., Jubb, R.W., McCabe, C.S., 2005. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (advance access published November 9, 2005).

British Medical Association, 1997 British Medical Association, Therapeutic Uses of Cannabis, Harwood Academic Publishers, Amsterdam (1997) 142 p..

Buggy et al., 2003 D.J. Buggy, L. Toogood, S. Maric, P. Sharpe, D.G. Lambert and D.J. Rowbotham, Lack of analgesic efficacy of oral ?-9-tetrahydrocannabinol in postoperative pain, Pain 106 (2003), pp. 169–172. SummaryPlus | Full Text + Links | PDF (83 K)

Burstein et al., 2004 S.H. Burstein, M. Karst, U. Schneider and R.B. Zurier, Ajulemic acid: a novel cannabinoid produces analgesia without a “high”, Life Sciences 75 (2004), pp. 1513–1522. SummaryPlus | Full Text + Links | PDF (152 K)

Cabral and Dove Pettit, 1998 G. Cabral and D.A. Dove Pettit, Drugs and immunity: cannabinoids and their role in decreased resistance to infectious diseases, Journal of Neuroimmunology 83 (1998), pp. 116–123. SummaryPlus | Full Text + Links | PDF (168 K)

Campbell et al., 2001 F.A. Campbell, M.R. Tramer, D. Carroll, J.M. Reynolds, R.A. Moore and H.J. McQuay, Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review, British Medical Journal 323 (2001), pp. 13–16. Abstract-EMBASE | Abstract-Elsevier BIOBASE

Carroll et al., 2004 C.B. Carroll, P.G. Bain, B.M. Teare, X. Liu, C. Joint, C. Wroath, S.G. Parkin, P. Fox, D. Wright, J. Hobart and J.P. Zajicek, Cannabis for dyskinesia in Parkinson disease. A randomized double-blind crossover study, Neurology 63 (2004), pp. 1245–1250. Abstract-Elsevier BIOBASE | Abstract-MEDLINE | Abstract-EMBASE

Carter et al., 2004 G.T. Carter, P. Weijdt, M. Kyashna-Tocha and D.I. Abrams, Medicinal cannabis: rational guidelines for dosing, Drugs 75 (2004), pp. 464–470. Abstract-MEDLINE

Chan et al., 1987 H.S.L. Chan, J.A. Correia and S.M. MacLeod, Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind crossover trial, Pediatrics 79 (1987), pp. 946–952. Abstract-EMBASE | Abstract-MEDLINE

Chang et al., 1981 A.E. Chang, D.J. Shiling, R.C. Stillman, N.H. Goldberg, C.A. Seipp, I. Barofsky and S.A. Rosenberg, A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy, Cancer 47 (1981), pp. 1746–1751. Abstract-MEDLINE | Abstract-EMBASE

Chang et al., 1979 A.E. Chang, D.J. Shiling, R.C. Stillman, N.H. Goldberg, C.A. Seipp, I. Barofsky, R.M. Simon and S.A. Rosenberg, Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate, Annals of Internal Medicine 91 (1979), pp. 819–824. Abstract-MEDLINE | Abstract-EMBASE

Clark, 2000 P.A. Clark, The ethics of medical marijuana: government restrictions vs medical necessity, Journal of Public Health Policy 21 (2000), pp. 40–60. Abstract-EMBASE | Abstract-MEDLINE

Clifford, 1983 D.B. Clifford, Tetrahydrocannabinol for tremor in multiple sclerosis, Annals of Neurology 13 (1983), pp. 669–671. Abstract-MEDLINE | Abstract-EMBASE | Full Text via CrossRef

Colls et al., 1980 B.M. Colls, D.G. Ferry, A.J. Gray, V.J. Harvey and E.G. McQueen, The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy, New Zealand Medical Journal 91 (1980), pp. 449–451. Abstract-MEDLINE | Abstract-EMBASE

Consroe, 1999 P. Consroe, Clinical and experimental reports of marihuana and cannabinoids in spastic disorders. In: G.G. Nahas, K.M. Sutin, D.J. Harvey and S. Agurelle, Editors, Marihuana and Medicine, Humana Press, Totowa (1999), pp. 611–617.

Consroe and Sandyk, 1992 P. Consroe and R. Sandyk, Potential role of cannabinoids for therapy of neurological disorders. In: L. Murphy and A. Bartke, Editors, Marijuana/Cannabinoids: Neurobiology and Neurophysiology, CRC Press, Boca Raton (1992), pp. 459–524.

Consroe et al., 1975 P. Consroe, J.C. Wood and H. Buchsbaum, Anticonvulsant nature of marihuana smoking, Journal of the American Medical Association 234 (1975), pp. 306–307. Abstract-MEDLINE

CPA, 2005 CPA, Compendium of Pharmaceuticals and Specialties, Canadian Pharmacists Association, Ottawa (2005) 2440 p..

Crawford and Buckman, 1986 S.M. Crawford and R. Buckman, Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double-blind study, Medical Oncology and Tumor Pharmacotherapy 3 (1986), pp. 39–42. Abstract-MEDLINE | Abstract-EMBASE

Croxford and Miller, 2004 J.L. Croxford and S.D. Miller, Towards cannabis and cannabinoid treatment of multiple sclerosis, Drugs Today 40 (2004), pp. 663–676. Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

Cunha et al., 1980 J.M. Cunha, E.A. Carlini, A.E. Pereira, O.L. Ramos, C. Pimentel, R. Gagliardi, W.L. Sanvito, N. Lander and R. Mechoulan, Chronic administration of cannabidiol to healthy volunteers and epileptic patients, Pharmacology 21 (1980), pp. 175–185. Abstract-MEDLINE | Abstract-EMBASE

Dalzell et al., 1986 A.M. Dalzell, H. Bartlett and J.S. Lilleyman, Nabilone: an alternative antiemetic for cancer chemotherapy, Archives of Disease in Childhood 61 (1986), pp. 502–505. Abstract-MEDLINE | Abstract-EMBASE

Degenhardt et al., 2003 L. Degenhardt, W. Hall and M. Lynskey, Testing hypotheses about the relationship between cannabis use and psychosis, Drug and Alcohol Dependence 71 (2003), pp. 37–48. SummaryPlus | Full Text + Links | PDF (446 K)

de Jong et al., 2005 F.A. de Jong, F.K. Engels, R.H. Mathijssen, L. van Zuylen, J. Verweig, R.P.H. Peters and A. Sparreboom, Medicinal cannabis in oncology practice: still a bridge too far?, Journal of Clinical Oncology 23 (2005), pp. 2886–2891. Abstract-MEDLINE | Full Text via CrossRef

Derkinderen et al., 2004 P. Derkinderen, E. Valjent, F. Darcel, P. Damier and J.A. Girault, Cannabis et récepteurs cannabinoïdes: de la physiopathologie aux possibilités thérapeutiques, Revue de Neurologie 160 (2004), pp. 639–649. Abstract-MEDLINE | Abstract-EMBASE

Devane et al., 1988 W.A. Devane, F.A. Dysark, M.R. Johnson, L.S. Melvin and A.C. Howlett, Determination and characterization of a cannabinoid receptor in rat brain, Molecular Pharmacology 34 (1988), pp. 605–613. Abstract-MEDLINE | Abstract-EMBASE

De Vries et al., 2001 T.J. De Vries, Y. Shaham, J.R. Homberg, H. Crombag, K. Schuurman, J. Dieben, L.J.M.J. Vanderschuren and A.N.M. Schoffelmeer, A cannabinoid mechanism in relapse to cocaine seeking, Nature Medicine 7 (2001), pp. 1151–1154. Abstract-MEDLINE | Abstract-Elsevier BIOBASE | Abstract-EMBASE | Full Text via CrossRef

Di Marzo et al., 2004 V. Di Marzo, M. Bifulco and L. De Petrocellis, The endocannabinoid system and its therapeutic exploitation, Nature Reviews 3 (2004), pp. 771–784. Abstract-EMBASE | Abstract-MEDLINE

Duran et al., 2004 M. Duran, J.R. Laporte and D. Capellà, Novedades sobre las potencialidades terapéuticas del cannabis y el sistema cannabinoide, Medicina Clinica 122 (2004), pp. 390–398. Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

Einhorn et al., 1981 L.H. Einhorn, C. Nagy, B. Furnas and S.D. William, Nabilone: an effective antiemetic in patients receiving cancer chemotherapy, Journal of Clinical Pharmacology 21 (1981), pp. 64S–69S. Abstract-MEDLINE

Ellison et al., 1990 J.M. Ellison, E. Gelwan and J. Ogletree, Complex partial seizure symptoms affected by marijuana abuse, Journal of Clinical Psychiatry 51 (1990), pp. 439–440. Abstract-MEDLINE | Abstract-EMBASE

Fankhauser, 2002 M. Fankhauser, Chapter 4: history of cannabis in Western medicine. In: F. Grotenhermen and R. Russo, Editors, Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, The Haworth Integrative Healing Press, New York (2002), pp. 37–51.

Fehr et al., 1983 K.O. Fehr, O.J. Kalant, H. Kalant and E.W. Single, Le cannabis: ses effets sur la santé, Psychotropes 1 (1983), pp. 115–121.

Fergusson et al., 2003 D.M. Fergusson, L.J. Horwood and N.R. Swain-Campbell, Cannabis dependence and psychotic symptoms in young people, Psychological medicine 33 (2003), pp. 15–21. Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

Fox et al., 2004 P. Fox, P.G. Bain, S. Glickman, C. Carrol and J. Zajicek, The effect of cannabis on tremor in patients with multiple sclerosis, Neurology 62 (2004), pp. 1105–1109. Abstract-EMBASE | Abstract-Elsevier BIOBASE | Abstract-MEDLINE

Fox et al., 2002 S.H. Fox, M. Kellett, A.P. Moore, A.R. Crossman and J.M. Brotchie, Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia, Movement Disorders 17 (2002), pp. 145–149. Abstract-MEDLINE | Abstract-Elsevier BIOBASE | Abstract-EMBASE | Full Text via CrossRef

Frytak et al., 1979 S. Frytak, C.G. Moertel, J.R. O’Fallon, J. Rubin, E.T. Creagah, M.J. O’Connell, A.J. Schutt and N.W. Schwartau, Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy, Annals of Internal Medicine 91 (1979), pp. 825–830. Abstract-EMBASE | Abstract-MEDLINE

Furler et al., 2004 M.D. Furler, T.R. Einarson, M. Millson, S. Walmsley and R. Bendayan, Medicinal and recreational marijuana use by patients infected with HIV, Aids Patient Care and STDs 18 (2004), pp. 215–228. Abstract-EMBASE | Abstract-MEDLINE

George et al., 1983 M. George, M.H. Pejovic, M. Thuaire, A. Kramar and J.P. Wolff, Essai comparatif randomisé d’un nouvel anti-émétique: la nabilone, chez des malades cancéreuses traitées par le cis-platinum, Biomedicine & Pharmacotherapy 37 (1983), pp. 24–27. Abstract-MEDLINE | Abstract-EMBASE

Gorter et al., 2005 R.W. Gorter, M. Butorac, E. Pulido Cobian and W. van der Sluis, Medical use of cannabis in the Netherlands, Neurology 64 (2005), pp. 917–919. Abstract-MEDLINE | Abstract-EMBASE | Abstract-Elsevier BIOBASE | Abstract-Elsevier BIOBASE

Gralla et al., 1984 R.J. Gralla, L.B. Tyson, L.A. Bordin, R.A. Clark, D.P. Kelsen, M.G. Kris, L.B. Kalman and S. Groshen, Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol, Cancer Treatment Reports 68 (1984), pp. 163–172. Abstract-EMBASE | Abstract-MEDLINE

Green, 1984 K. Green, Chapter 21: marijuana effects on intraocular pressure. In: S.M. Drance and A.H. Neufeld, Editors, Glaucoma: Applied Pharmacology in Medical Treatment, Grune & Stratton, Orlando (1984), pp. 507–526.

Greenberg et al., 1994 H.S. Greenberg, S.A.S. Werness, J.E. Pugh, R.O. Andrus, D.J. Anderson and E.F. Domino, Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers, Clinical Pharmacology and Therapeutics 55 (1994), pp. 324–328. Abstract-EMBASE | Abstract-MEDLINE

Grinspoon and Bakalar, 1997 L. Grinspoon and J.B. Bakalar, Marihuana. The Forbidden Medicine, Yale University Press, New Haven (1997) 296 p..

Gurley et al., 1998 R.J. Gurley, R. Aranow and M. Katz, Medicinal marijuana: a comprehensive review, Journal of Psychoactive Drugs 30 (1998), pp. 137–147. Abstract-MEDLINE | Abstract-EMBASE

Hall and Solowij, 1998 W. Hall and N. Solowij, Adverse effects of cannabis, The Lancet 352 (1998), pp. 1611–1616. SummaryPlus | Full Text + Links | PDF (133 K)

Hanigan et al., 1986 W.C. Hanigan, R. Destree and X.T. Truong, The effect of ?9-THC on human spasticity, Clinical Pharmacology and Therapeutics 39 (1986), p. 198.

Hartel, 1999 C.R. Hartel, Therapeutic uses of cannabis and cannabinoids. In: H. Kalant, W.A. Corrigal, W. Hall and R.G. Smart, Editors, The Health Effects of Cannabis, Center for Addiction and Mental Health, Toronto (1999), pp. 461–474.

Health Canada/CIHR, 1999 Health Canada/CIHR, Medical Marihuana Research Program, Health Canada and Canadian Institutes of Health Research, Ottawa (1999) 7 p..

Health Canada, 2005 Health Canada, Medical Use of Marihuana. Stakeholder Statistics, Office of Cannabis Medical Access, Health Canada, Ottawa (2005) 2 p..

Hepler et al., 1976 R.S. Hepler, I.M. Frank and R. Petrus, Ocular effects of marihuana smoking. In: M.C. Braude and S. Szara, Editors, The Pharmacology of Marihuana, Raven Press, New York (1976), pp. 815–824.

Herman et al., 1979 T.S. Herman, L.H. Einhorn, S.E. Jones, C. Nagy, M.B. Chester, J. Dean, M.S. Becky Furnas, S.D. William, S.A. Leigh, R.T. Dorr and T.E. Moon, Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy, New England Journal of Medicine 300 (1979), pp. 1295–1297. Abstract-EMBASE | Abstract-MEDLINE

Hoey, 2001 J. Hoey, Editorial. Marijuana: federal smoke clears a little, Canadian Medical Association Journal 164 (2001), p. 1397.

Holdcroft et al., 1997 A. Holdcroft, M. Smith, A. Jacklin, H. Hodgson, B. Smith, M. Newton and F. Evans, Pain relief with oral cannabinoids in familial Mediterranean fever, Anaesthesia 52 (1997), pp. 483–488.

HLSCST, 1998 House of Lords, Select Committee on Science and Technology, Cannabis: The Scientific and Medical Evidence, The Stationery Office, London (1998).

Hutcheon et al., 1983 A.W. Hutcheon, J.B.D. Palmer, M. Soukop, D. Cunningham, C. McArdle, J. Welsh, F. Stuart, G. Sangster, S. Kaye, D. Charlton and H. Cash, A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy, European Journal of Cancer and Clinical Oncology 19 (1983), pp. 1087–1090. Abstract-EMBASE | Abstract-MEDLINE

Institute of Medicine, 1999 Institute of Medicine, Marijuana and medicine. Assessing the science base. In: J.E. Joy, S.J. Watson Jr. and J.A. Benson Jr., Editors, Division of Neuroscience and Behavioral Health, Institute of Medicine, National Academy Press, Washington, DC (1999) 267 pp.

Iversen, 2003 L. Iversen, Cannabis and the brain, Brain 126 (2003), pp. 1252–1270. Abstract-MEDLINE | Abstract-EMBASE | Abstract-Elsevier BIOBASE | Full Text via CrossRef

Iversen, 2000 L. Iversen, Chapter 4: medical uses of marijuana. Fact or fantasy?. In: L. Iversen, Editor, The Science of Marijuana, Oxford University Press, Oxford (2000), pp. 121–175.

Jain et al., 1981 A.K. Jain, J.R. Ryan, G. McMahon and G. Smith, Evaluation of intramuscular levonantradol and placebo in acute postoperative pain, Journal of Clinical Pharmacology 21 (1981), pp. 320S–326S. Abstract-MEDLINE

Järvinen et al., 2002 T. Järvinen, D.W. Pate and K. Laine, Cannabinoids in the treatment of glaucoma, Pharmacology and Therapeutics 95 (2002), pp. 203–220. SummaryPlus | Full Text + Links | PDF (354 K)

Jatoi et al., 2002 A. Jatoi, H.E. Windschitl, C.L. Loprinzi, J.A. Sloan, S.R. Dakhil, J.A. Mailliard, S. Pundaleeka, C.G. Kardinal, T.R. Fitch, J.E. Krook, P.J. Novotny and B. Christensen, Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North central cancer treatment group study, Journal of Clinical Oncology 20 (2002), pp. 567–573. Abstract-EMBASE | Abstract-Elsevier BIOBASE | Abstract-MEDLINE | Full Text via CrossRef

Jochimsen et al., 1978 P.R. Jochimsen, R.L. Lawton, K. VerSteeg and R. Noyes Jr., Effect of benzopyranoperidine a ?-9-THC congener, on pain, Clinical Pharmacology and Therapeutics 24 (1978), pp. 223–227. Abstract-EMBASE | Abstract-MEDLINE

Johansson et al., 1982 R. Johansson, P. Kilkku, M. Groenroos and A. Robertone, A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy, Cancer Treatment Reviews 9 (1982), pp. 25–33. Abstract-MEDLINE | Abstract-EMBASE

Jones et al., 1982 S.E. Jones, J.R. Durant, F.A. Greco and A. Robertone, A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting, Cancer Treatment Reviews 9 (1982), pp. 45–48. Abstract-MEDLINE | Abstract-EMBASE

Jordan et al., 2005 K. Jordan, C. Kasper and H.J. Schmoll, Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment, European Journal of Cancer 41 (2005), pp. 199–205. SummaryPlus | Full Text + Links | PDF (262 K)

Karst et al., 2003 M. Karst, K. Salim, S. Burstein, I. Conrad, L. Hoy and U. Schneider, Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled trial, Journal of the American Medical Association 290 (2003), pp. 1757–1762. Abstract-Elsevier BIOBASE | Abstract-MEDLINE | Full Text via CrossRef

Kaslow et al., 1989 R.A. Kaslow, W.C. Blackwelder, D.G. Ostrow, D. Yerg, J. Palenicek, A.H. Coulson and R.O. Valdiserri, No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals, Journal of the American Medical Association 261 (1989), pp. 3424–3429. Abstract-EMBASE | Abstract-MEDLINE

Killestein et al., 2004 J. Killestein, B.M.J. Uitdehaag and C.H. Polman, Cannabinoids in multiple sclerosis. Do they have a therapeutic role?, Drugs 64 (2004), pp. 1–11. Abstract-Elsevier BIOBASE | Abstract-MEDLINE | Full Text via CrossRef

Killestein et al., 2003 J. Killestein, E.L.J. Hoogervorst and M. Reif et al., Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis, Journal of Neuroimmunology 137 (2003), pp. 140–143. SummaryPlus | Full Text + Links | PDF (86 K)

Killestein et al., 2002 J. Killestein, E.L.J. Hoogervorst, M. Reif, N.F. Kalkers, A.C. van Loenen, P.G.M. Staats, R.W. Gorter, B.M.J. Uitdehaag and C.H. Polman, Safety, tolerability, and efficacy of orally administered cannabinoids in MS, Neurology 58 (2002), pp. 1404–1407. Abstract-EMBASE | Abstract-Elsevier BIOBASE | Abstract-MEDLINE

Kleber et al., 1997 H.D. Kleber, J.A. Califano Jr. and J.C. Demers, Chapter 82: clinical and societal implications of drug legalization. In: J.H. Lowinson, P. Ruiz, R.B. Millman and J.G. Langrod, Editors, Substance Abuse. A Comprehensive Textbook (3rd ed.), Williams & Wilkins, Baltimore (1997), pp. 855–864.

Kluin-Neleman et al., 1979 J.C. Kluin-Neleman, F.A. Neleman, O.J.A. Meuwissen and R.A.A. Maes, Delta-9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy: a double-blind cross-over trial against placebo, Veterinarian and Human Toxicology 21 (1979), pp. 338–340. Abstract-EMBASE | Abstract-MEDLINE

Kraft and Kress, 2004 B. Kraft and H.G. Kress, Cannabinoids and the immune system of men, mice and cells, Der Schmerz 18 (2004), pp. 203–210. Abstract-EMBASE | Abstract-MEDLINE

Labigalini et al., 1999 E. Labigalini Jr., L.R. Rodrigues and D.X. Da Silveira, Therapeutic use of cannabis by crack addicts in Brazil, Journal of Psychoactive Drugs 31 (1999), pp. 451–455. Abstract-MEDLINE | Abstract-EMBASE

Lane et al., 1991 M. Lane, C.L. Vogel, J. Ferguson, S. Krasnow, J.L. Saiers, J. Hamm, K. Salva, P.H. Wiernik, C.P. Holroyde, S. Hammil, K. Shepard and T. Plasse, Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting, Journal of Pain and Symptom Management 6 (1991), pp. 352–359. Abstract

Levitt, 1982 M. Levitt, Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients, Cancer Treatment Reviews 9 (1982), pp. 49–53. Abstract-MEDLINE | Abstract-EMBASE

Levitt et al., 1984 M. Levitt, C. Faiman, R. Hawks and A. Wilson, Randomized double-blind comparison of delta-9-tetrahydrocannabinol (THC) and marijuana as chemotherapy antiemetics, Proceedings of the American Society of Clinical Oncology 3 (1984), p. 91.

Li, 1974 H.L. Li, An archaelogical and historical account of cannabis in China, Economic Botany 28 (1974), pp. 437–448.

Lindstrom et al., 1987 P. Lindstrom, U. Lindblom and L. Boreus, Lack of effect of cannabidiol in sustained neuropathia, Proceedings of the Marijuana 1987 International Conference on Cannabis Melbourne, September 2–4 (1987).

Lynch and Clark, 2003 M.A. Lynch and A.J. Clark, Cannabis reduces opioid dose in the treatment of chronic non-cancer pain, Journal of Pain and Symptom Management 25 (2003), pp. 496–498. SummaryPlus | Full Text + Links | PDF (46 K)

Macleod et al., 2004 J. Macleod, R. Oakes, A. Copello, I. Crome, M. Egger, M. Hickman, T. Oppenkowski, H. Stokes-Lampard and G.A. Smith, Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies, The Lancet 363 (2004), pp. 1579–1588. SummaryPlus | Full Text + Links | PDF (119 K)

Maldonado and Valverde, 2003 R. Maldonado and O. Valverde, Participation of the opioid system in cannabinoid-induced anticiception and emotional-like responses, European Neuropsychopharmacology 13 (2003), pp. 401–410. SummaryPlus | Full Text + Links | PDF (168 K)

Martyn et al., 1995 C.N. Martyn, L.S. Illis and J. Thom, Nabilone in the treatment of multiple sclerosis, The Lancet 345 (1995), p. 579. SummaryPlus | Full Text + Links | PDF (138 K)

Matsuda et al., 1990 L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young and T.I. Bonner, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature 346 (1990), pp. 561–564. Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

Maurer et al., 1990 M. Maurer, V. Henn, A. Dittrich and A. Hofmann, Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial, European Archives of Psychiatry and Clinical Neurosciences 240 (1990), pp. 1–4. Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

McCabe et al., 1988 M. McCabe, F.P. Smith, J.S. Macdonald, P.V. Woolley, D. Goldberg and P.S. Schein, Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy, Investigational New Drugs 6 (1988), pp. 243–246. Abstract-EMBASE | Abstract-MEDLINE

McKim, 2000 W.A. McKim, Drugs and Behavior. An Introduction to Behavioral Pharmacology (4th ed.), Prentice-Hall, Upper Saddle River (2000) 400 p..

Mechoulam, 1986 R. Mechoulam, Chapter 1: the pharmacohistory of Cannabis sativa. In: R. Mechoulan, Editor, Cannabinoids as Therapeutic Agents, CRC Press, Boca Raton (1986), pp. 1–19.

Merritt et al., 1980 J.C. Merritt, W.J. Crawford, P.C. Alexander, A.L. Anduze and S.S. Gelbart, Effect of marihuana on intraocular and blood pressure in glaucoma, Ophtalmology 87 (1980), pp. 222–228. Abstract-MEDLINE | Abstract-EMBASE

Merritt et al., 1981 J.C. Merritt, J.L. Olsen, J.R. Armstrong and S.M. McKinnon, Topical ?9-tetrahydrocannabinol in hypertensive glaucomas, Journal of Pharmacy and Pharmacology 33 (1981), pp. 40–41. Abstract-EMBASE | Abstract-MEDLINE

Mirken, 2004 B. Mirken, Marijuana on the state, The Lancet 364 (2004), p. 842. SummaryPlus | Full Text + Links | PDF (60 K)

Müller-Vahl et al., 2002a K.R. Müller-Vahl, U. Schneider, A. Koblenz, M. Jobges, H. Kolbe, T. Daldrup and H.M. Emrich, Treatment of Tourette's syndrome with ?9-tetrahydrocannabinol (THC): a randomized crossover trial, Pharmacopsychiatry 35 (2002), pp. 57–61. Abstract-MEDLINE | Full Text via CrossRef

Müller-Vahl et al., 2002b K.R. Müller-Vahl, H. Kolbe, U. Schneider and H.M. Emrich, Chapter 18: Movement disorders. In: F. Grotenhermen and E. Russo, Editors, Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential, The Haworth Integrative Healing Press, New York (2002), pp. 205–214.

Müller-Vahl et al., 2003a K.R. Müller-Vahl, U. Schneider, H. Prevedel, K. Theloe, H. Kolbe, T. Daldrup and H.M. Emrich, ?9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial, Journal of Clinical Psychiatry 64 (2003), pp. 459–465. Abstract-MEDLINE

Müller-Vahl et al., 2003b K.R. Müller-Vahl, H. Prevedel, K. Theloe, H. Kolbe, H.M. Emrich and U. Schneider, Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (?9-THC): no influence on neuropsychological performance, Neuropharmacology 28 (2003), pp. 384–388. Abstract-MEDLINE | Full Text via CrossRef

Müller-Vahl, 2003 K.R. Müller-Vahl, Cannabinoids reduce symptoms of Tourette's syndrome, Expert Opinion on Pharmacotherapy 4 (2003), pp. 1717–1725. Abstract-MEDLINE | Full Text via CrossRef

Munro et al., 1993 S. Munro, K.L. Thomas and M. Abu-Shaar, Molecular characterization of a peripheral receptor for cannabinoids, Nature 365 (1993), pp. 61–65. Abstract-MEDLINE | Abstract-EMBASE | Full Text via CrossRef

Naef et al., 2003 M. Naef, M. Curatolo, S. Petersen-Felix, L. Arendt-Nielsen, A. Zbinden and R. Brenneisen, The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC–morphine combination in healthy subjects under experimental pain conditions, Pain 105 (2003), pp. 79–88. SummaryPlus | Full Text + Links | PDF (458 K)

Neidhart et al., 1981 J.A. Neidhart, M.M. Gagen, H.E. Wilson and D.C. Young, Comparative trial of the antiemetic effects of THC and haloperidol, Journal of Clinical Pharmacology 21 (1981), pp. 38S–42S. Abstract-MEDLINE

Niederle et al., 1986 N. Niederle, J. Schiitte and C.G. Schmidt, Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy, Klinische Wochen-Schrift 64 (1986), pp. 362–365. Abstract-MEDLINE | Abstract-EMBASE | Full Text via CrossRef

Niiranen and Mattson, 1985 A. Niiranen and K. Mattson, A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy, American Journal of Clinical Oncology 8 (1985), pp. 336–340. Abstract-MEDLINE | Abstract-EMBASE

Nolin et al., 2002 Nolin, P.C., Kenny, C., Banks, T., Maheu, S., Rossiter, E., 2002. Cannabis: our position for a Canadian Public Policy. Report of the Senate Special Committee on Illegal Drugs. Senate of Canada, Ottawa, 706 p.

Notcutt et al., 2004 W. Notcutt, M. Price, R. Miller, S. Newport, C. Phillips, S. Simmons and C. Sansom, Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies, Anaesthesia 59 (2004), pp. 440–452. Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

Noyes et al., 1975a R. Noyes Jr., S.F. Brunk, D.H. Avery and A. Canter, The analgesic properties of delta-9-tetrahydrocannabinol and codeine, Clinical Pharmacology and Therapeutics 18 (1975), pp. 84–89. Abstract-MEDLINE

Noyes et al., 1975b R. Noyes Jr., S.F. Brunk, D.A. Baram and A. Canter, Analgesic effect of delta-9-tetrahydrocannabinol, Journal of Clinical Pharmacology 15 (1975), pp. 139–143. Abstract-EMBASE | Abstract-MEDLINE

Office of Medicinal Cannabis, 2005 Office of Medicinal Cannabis, On the Office of Medicinal Cannabis and its Products, Ministry of Health, Welfare and Sports of the Netherlands (2005) 1 p..

Orr et al., 1980 L.E. Orr, J.F. McKernan and B. Bloome, Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis, Archives of Internal Medicine 140 (1980), pp. 1431–1433. Abstract-MEDLINE | Abstract-EMBASE

O'Shaugnessy, 1838–1840 W.B. O'Shaugnessy, On the preparations of the Indian hemp, or gunjah (Cannabis indica): their effets on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases, Transactions of Medical and Physical Society of Bengal (1838–1840), pp. 421–461.

Pacifici et al., 2003 R. Pacifici, P. Zuccaro, S. Pichini, P.R. Roset, S. Poudevida, M. Farré, J. Segura and R. de la Torre, Modulation of the immune system in cannabis users, Journal of the American Medical Association 289 (2003), pp. 1929–1931. Abstract-MEDLINE | Abstract-Elsevier BIOBASE

Perrot, 2004 S. Perrot, Cannabis: the analgesic and antiinflammatory medication of the future?, Joint Bone Spine 71 (2004), pp. 7–8. SummaryPlus | Full Text + Links | PDF (100 K)

Pertwee, 2002 R.G. Pertwee, Cannabinoids and multiple sclerosis, Pharmacology and Therapeutics 95 (2002), pp. 165–174. SummaryPlus | Full Text + Links | PDF (150 K)

Petro, 1997 D.J. Petro, Chapter 9: spasticity and chronic pain. In: M.L. Mathre, Editor, Cannabis in Medical Practice. A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana, McFarland and Co., Jefferson (1997), pp. 112–124.

Petro and Ellenberger, 1981 D.J. Petro and C. Ellenberger, Treatment of human spasticity with ?-9-tetrahydrocannabinol, Journal of Clinical Pharmacology 21 (1981), pp. 413S–416S. Abstract-MEDLINE

Phillips et al., 2002 L.J. Phillips, C. Curry, A.R. Yung, H. Pan Yuen, S. Adlard and P.D. McGorry, Cannabis use is not associated with the development of psychosis in an ‘ultra’ high-risk group, Australian and New Zealand Journal of Psychiatry 36 (2002), pp. 800–806. Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

Piomelli, 2001 D. Piomelli, Cannabinoid activity curtails cocaine craving, Nature Medicine 7 (2001), pp. 1099–1100. Abstract-MEDLINE | Abstract-Elsevier BIOBASE | Abstract-EMBASE | Full Text via CrossRef

Pomeroy et al., 1986 M. Pomeroy, J.J. Fennelly and M. Towers, Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis, Cancer Chemotherapy and Pharmacology 17 (1986), pp. 285–288. Abstract-MEDLINE | Abstract-EMBASE

Pryce and Baker, 2005 G. Pryce and D. Baker, Emerging properties of cannabinoid medicines in management of multiple sclerosis, Trends in Neurosciences 28 (2005), pp. 272–276. SummaryPlus | Full Text + Links | PDF (112 K)

Raft et al., 1977 D. Raft, J. Gregg, J. Ghia and L. Harris, Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response, Clinical Pharmacology and Therapeutics 21 (1977), pp. 26–33. Abstract-MEDLINE | Abstract-EMBASE

Regelson et al., 1976 W. Regelson, J.R. Butler, J. Schulz, T. Kirk, L. Peek, M.L. Green and M.O. Zalis, ?9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: M.C. Braude and S. Szara, Editors, The Pharmacology of Marihuana, Raven Press, New York (1976), pp. 763–776.

Robson, 2001 P. Robson, Therapeutic aspects of cannabis and cannabinoids, British Journal of Psychiatry 178 (2001), pp. 107–115. Abstract-MEDLINE | Abstract-EMBASE | Abstract-Elsevier BIOBASE | Full Text via CrossRef

Rog et al., 2005 D.J. Rog, T.R. Nurmikko, T. Friede and C.A. Young, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis, Neurology 65 (2005), pp. 812–819. Abstract-Elsevier BIOBASE | Abstract-MEDLINE

Roncoroni, 2003 A.J. Roncoroni, Uso médico de la marihuana y canabinoides sintéticos, Medicina 63 (2003), pp. 748–752. Abstract-MEDLINE

Roth et al., 2002 M.D. Roth, G.C. Baldwin and D.P. Tashkin, Effects of delta-9-tetrahydrocannabinol on human immune function and host defense, Chemistry and Physics of Lipids 121 (2002), pp. 229–239. SummaryPlus | Full Text + Links | PDF (150 K)

Sallan et al., 1980 S.E. Sallan, C. Cronin, M. Zelen and N.E. Zinberg, Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine, New England Journal of Medicine 302 (1980), pp. 135–138. Abstract-EMBASE | Abstract-MEDLINE

Sallan et al., 1975 S.E. Sallan, N.E. Zinberg and E. Frei, Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy, New England Journal of Medicine 293 (1975), pp. 795–797. Abstract-EMBASE | Abstract-MEDLINE

Segal, 1986 M. Segal, Cannabinoids and analgesia. In: R. Mechoulam, Editor, Cannabinoids as Therapeutic Agents, CRC Press, Boca Raton (1986), pp. 105–120.

Sieradzan et al., 2001 K.A. Sieradzan, S.H. Fox, M. Hill, J.P.R. Dick, A.R. Crossman and J.M. Brotchie, Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study, Neurology 57 (2001), pp. 2108–2111. Abstract-MEDLINE | Abstract-EMBASE | Abstract-Elsevier BIOBASE

Smith, 1998 D.E. Smith, Review of the American Medical Association Council on Scientific Affairs Report on Medical Marijuana, Journal of Psychoactive Drugs 30 (1998), pp. 127–136. Abstract-MEDLINE | Abstract-EMBASE

Smith, 2004 P.F. Smith, Medicinal cannabis extracts for the treatment of multiple sclerosis, Current Opinion in Investigational Drugs 5 (2004), pp. 727–730. Abstract-MEDLINE

Söderpalm et al., 2001 A.H.V. Söderpalm, A. Schuster and H. de Wit, Antiemetic efficacy of smoked marijuana. Subjective and behavioral effects on nausea induced by syrup of ipecac, Pharmacology, Biochemistry and Behavior 69 (2001), pp. 343–350. SummaryPlus | Full Text + Links | PDF (370 K)

Solomon, 1968 D. Solomon, The Marihuana Papers, Bobbs-Merril, Indianapolis (1968) 510 p..

Staquet et al., 1978 M. Staquet, C. Gantt and D. Machin, Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain, Clinical Pharmacology and Therapeutics 23 (1978), pp. 397–401. Abstract-EMBASE | Abstract-MEDLINE

Steele et al., 1980 N. Steele, R.J. Gralla, D.W. Braun and C.W. Young, Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis, Cancer Treatment Reports 64 (1980), pp. 219–224. Abstract-EMBASE | Abstract-MEDLINE

Struwe et al., 1993 M. Struwe, S.H. Kaempfer, C.J. Geiger, A.T. Pavia, T.F. Plasse, K.V. Shepard, K. Ries and T.G. Evans, Effect of dronabinol on nutritional status in HIV infection, Annals of Pharmacotherapy 27 (1993), pp. 827–831. Abstract-EMBASE | Abstract-MEDLINE

Svendsen et al., 2004 K.B. Svendsen, T.S. Jensen and F.W. Back, Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial, British Medical Journal 329 (2004), pp. 253–261.

Tramer et al., 2001 M.R. Tramer, D. Carroll, F.A. Campbell, D.J.M. Reynolds, R.A. Moore and H.J. McQuay, Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review, British Medical Journal 323 (2001), pp. 1–8.

Ungerleider et al., 1987 J.T. Ungerleider, T. Andrysiak, L. Fairbanks, G.W. Ellison and L.W. Myers, Delta-9-THC in the treatment of spasticity associated with multiple sclerosis, Advances in Alcohol and Substance Abuse 7 (1987), pp. 39–50. Abstract-MEDLINE | Abstract-EMBASE

Ungerleider et al., 1982 J.T. Ungerleider, T. Andrysiak, L. Fairbanks, J. Goodnight, G. Sarna and K. Jamison, Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine, Cancer 50 (1982), pp. 636–645. Abstract-MEDLINE | Abstract-EMBASE

Vaney et al., 2004 C. Vaney, M. Heinzel-Gutenbrunner, P. Jobin, F. Tschopp, B. Gattlen, U. Hagen and M. Schnelle, Efficacy, safety and tolerability of an oral administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study, Multiple Sclerosis 10 (2004), pp. 417–424. Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

van Hoozen and Cross, 1997 B.E. van Hoozen and C.E. Cross, Marihuana: respiratory tract effects, Clinical Review of Allergy and Immunology 15 (1997), pp. 243–269. Abstract-MEDLINE

van Os et al., 2002 J. van Os, M. Bak, M. Hanssen, R.V. Bijl, R. de Graaf and H. Verdoux, Cannabis use and psychosis: a longitudinal population-based study, American Journal of Epidemology 156 (2002), pp. 319–327. Abstract-GEOBASE | Abstract-MEDLINE | Abstract-EMBASE | Abstract-Elsevier BIOBASE | Full Text via CrossRef

Wada et al., 1982 J.K. Wada, D.L. Bogdon, J.C. Gunnell, G.J. Hum, C.H. Gota and T.E. Rieth, Double-blind, randomized, crossover trial of nabilone vs placebo in cancer chemotherapy, Cancer Treatment Reviews 9 (1982), pp. 39–44. Abstract-MEDLINE | Abstract-EMBASE

Wade et al., 2004 D.T. Wade, P. Makela, P. Robson, H. Houre and C. Bateman, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients, Multiple Sclerosis 10 (2004), pp. 434–441. Abstract-MEDLINE | Abstract-EMBASE | Full Text via CrossRef

Wade et al., 2003 D.T. Wade, P. Robson, H. House, P. Makela and J. Aram, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms, Clinical Rehabilitation 17 (2003), pp. 21–29. Abstract-MEDLINE | Abstract-EMBASE | Full Text via CrossRef

Walsh et al., 2003 D. Walsh, K.A. Nelson and F.A. Mahmoud, Established and potential therapeutic applications of cannabinoids in oncology, Support Care Cancer 11 (2003), pp. 137–143. Abstract-EMBASE | Abstract-MEDLINE

Wingerchuk, 2004 D. Wingerchuk, Cannabis for medical purposes: cultivating science, weeding out the fiction, The Lancet 364 (2004), pp. 315–316. SummaryPlus | Full Text + Links | PDF (43 K)

Yamamoto et al., 2004 T. Yamamoto, K. Anggadiredja and T. Hiranita, New perspectives in the studies on endocannabinoid and cannabis: a role for the endocannabinoid–arachidonic acid pathway in drug reward and long-lasting relapse to drug taking, Journal of Pharmacological Sciences 96 (2004), pp. 382–388. Abstract-EMBASE | Abstract-Elsevier BIOBASE | Abstract-MEDLINE | Full Text via CrossRef

Zajicek et al., 2003 J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn and A. Thompson, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomised placebo-controlled trial, The Lancet 362 (2003), pp. 1517–1526. SummaryPlus | Full Text + Links | PDF (132 K)

Zajicek et al., 2005 J.P. Zajicek, H.P. Sanders, D.E. Wright, J.P. Vickery, W.M. Ingram, S.M. Reilly, A.J. Nunn, L.J. Teare, P.J. Fox and A.J. Thompson, Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up, Journal of Neurology, Neurosurgery and Psychiatry 76 (2005), pp. 1664–1669. Abstract-Elsevier BIOBASE | Abstract-EMBASE | Abstract-MEDLINE | Full Text via CrossRef

Zammit et al., 2002 S. Zammit, P. Allebeck, S. Andreasson, I. Lundberg and G. Lewis, Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969; historical cohort study, British Medical Journal 325 (1969), pp. 1199–1201.

Zhu et al., 2000 L.X. Zhu, S. Sharma, M. Stolina, B. Gardner, M.D. Roth, D.P. Tashkin and S.M. Dubinett, D9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependant pathway, Journal of Immunology 165 (2000), pp. 373–380. Abstract-Elsevier BIOBASE | Abstract-EMBASE | Abstract-MEDLINE

[Full Text of this Article in Adobe PDF format]

[END]